8 diverse MUSIC practices. Data abstractors recorded clinical, radiographic, pathologic, surgical, and short-term follow-up data into the registry for patients with a newly-diagnosed RM 7cm.
INTRODUCTION AND OBJECTIVES:
The average length of stay following robotic-assisted radical prostatectomy (RARP) is 24-48hrs and potentially longer on average in community settings. If safe, same day discharge (SDD) following RARP could allow considerable cost savings. The largest previous reports of SDD after RARP include less than 50 highly-selected patients. We report our experience routinely offering SDD after RARP in a community setting and evaluate the safety and cost implications.
METHODS: Beginning September 2016, we adjusted our RARP clinical pathway to allow SDD. This included using ultra-low pneumoperitoneum at 6mmHg, immediate ambulation, immediate diet, and scheduled non-narcotic analgesia with optional oral but no intravenous narcotics. Patients were given the option for SDD without it being mandated. After allowing a period of three months to solidify the protocol, we evaluated our prospective database for the next 500 consecutive patients to determine the success rate and safety of SDD.
RESULTS: Of 500 consecutive RARPs performed in 18 months, 246 patients (49.2%) were discharged the day of surgery with all of the remaining 254 discharged the next day for a mean length of stay of 0.51 days. Characteristics included mean age 62yrs (range, 42-81yrs) and BMI 29.7kg/m 2 (range, 20-53kg/m 2 ). All patients underwent lymphadenectomy with yield of 8.1 nodes (range, 2-24) with OR time of 161min and blood loss of 135mL with no transfusions. Thirty-four patients (6.8%) overall had a Clavien-Dindo grade I-III complication within 90 days of surgery with no grade IV-V complications, of which only 5 required a visit to the emergency department (1%) and only 8 required readmission (1.6%). Among patients discharged on the day of surgery, only one was readmitted (for deep vein thrombosis), and only one presented to the emergency department (for occluded catheter). The estimated charge for overnight postoperative admission at our institution is $2,109, such that the approximate reduction in charges was $518,814 over 18 months ($345,876/yr) with no increase in costs from emergency room visits or readmissions as compared with patients who stayed longer. Among the most recent 200 patients, the rate of SDD improved to 52.5%, and in the most recent 100 patients it improved to 65%.
CONCLUSIONS: Same-day discharge following RARP can be applied safely in a subset of patients with no increase in readmissions or emergency visits and may lead to significant savings in healthcare costs. To our knowledge, this is only large series examining the safety and feasibility of SDD after RARP reported to date. We developed a novel approach to extract both anticipated and actual trial accrual. We apply these previously unavailable data to describe accrual adequacy and identify predictors of poor accrual.
METHODS: Records for all GU cancer clinical trials started since 2005 were extracted from ClinicalTrials.gov. We employed a custom Python web scraper to extract anticipated and actual accrual information and trial characteristics from the ClinicalTrials.gov archives. Logistic regression was used to identify predictors of failing to meet 50% or 85% of anticipated accrual.
RESULTS: A total of 3,976 completed or terminated genitourinary cancer trials were extracted, of which 1,322 unique trials had complete records. Only 42% of trials met their anticipated accrual goals, and 30% enrolled fewer than half of their anticipated patients (Table) . Of trials reported as completed, only 54% reached their accrual goals; 17% failed to reach 50% of anticipated accrual. On logistic regression, prostate (OR 0.64, 95% CI 0.45-0.91) and testicular (OR 0.44, 95% CIINTRODUCTION AND OBJECTIVES: In 2013, Kaiser Permanente developed a risk stratification tool: Hematuria Risk Index (HRI) to further subdivide hematuria patients. Patients were assigned points based on clinical characteristics and three risk groups were developed with varying rates of cancer detection. The low risk (0-4 points) group had a 0-0.3% rate of cancer detection, moderate risk (5-8 points) 1.1-2.5% rate, and high risk (9-11 points) 10.7-11.6%. We applied the HRI stratification model to our cohort of AMH patients in order to externally validate this model and to perform a cost analysis based on the risk stratifications.
METHODS: A retrospective review was performed of patients who underwent AMH evaluation from 2012 e 2015 at a single institution. After excluding for incomplete evaluation or lack of follow up, 994 patients were included. HRI scores were determined for each patient. Total number of tumors and studies performed in the work up were determined for each of the groups. Cost of tests were estimated based on published Medicare averages from a recent JAMA study.
RESULTS: The Kaiser HRI was validated in our patient cohort and found to be statistically significant for finding cancer in each group (p<0.0001). If no low risk patients were screened, 0 cancers would have been missed and estimated cost would have decreased to $166,252 from $408,376. If no low risk patients as well as no HRI 5&6 patients with either a history of stones or current AC use were screened, cost would have decreased to $130,169 with 0 cancers missed. A receiver operator curve (ROC) generated for HRI and cancer detection had an area under curve (AUC) of 0.885.
CONCLUSIONS: The HRI provided a risk stratification model that would have minimized cost while avoiding missed cancer diagnoses. The low risk group could have avoided work up without missing a single tumor. Other factors such stone history or AC use may be able to be incorporated into the algorithm. The cost benefit analysis in our cohort shows a significant cost savings with minimal loss in cancer detection based on HRI and imaging modality.
Source of Funding: none
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